Table 2. Comparison of ocular manifestations between euthyroid (group A) and hyperthyroid TAO (group B).
| Group A (n=24) |
Group B (n=139) |
P-value | |
|---|---|---|---|
| Remission of hyperthyroidism (n=10) | |||
| Asymmetric involvement (number (%)) | 19 (79.2%) | 38 (27.3%) | <0.001a |
| 3 (30.0%) | 0.015a | ||
| Clinical activity score (mean (SD)) | 1.50 (1.3) | 2.26 (1.7) | 0.014a |
| 1.10 (1.7) | 0.381 | ||
| NOSPECS score (mean (SD)) | 3.38 (1.4) | 4.13 (2.4) | 0.037a |
| 2.60 (1.3) | 0.196 | ||
| Optic neuropathy (number (%)) | 0 (0%) | 8 (5.7%) | 0.216 |
| 0 (0%) | — | ||
| Restrictive myopathy (number (%)) | 6 (25.0%) | 43 (30.9%) | 0.558 |
| 3 (30.0%) | 0.667 | ||
| Exophthalmometry value (mean (SD)) | 17.04 (3.71) | 18.56 (3.19) | 0.149 |
| 16.40 (2.56) | 0.322 | ||
| Lid retraction (number (%)) | 22 (91.7%) | 92 (66.2%) | 0.014a |
| 5 (50.0%) | 0.014a |
Abbreviation: TAO, thyroid-associated ophthalmopathy.
Wilcoxon rank-sum test for comparison of clinical activity score, NOSPECS score, and the mean value of exophthalmometry.
Chi-square test or Fisher's exact test for comparison of categorical variables.
a
P<0.05 was considered statistically significant.